FocusOn Neurology
  • Gastrointestinal Resource Center
  • Inflammatory Bowel Disease
  • NASH Resource Center
  • Highlights from DDW 2025
  • Highlights from ACG 2025 - Focus on Ulcerative Colitis
  • Highlights from ACG 2026 - Focus on Ulcerative Colitis
  • Highlights from ACG 2025 - Focus on Metabolic Dysfunction–Associated Steatohepatitis (MASH)
  • Highlights from ACG 2026 - Focus on Metabolic Dysfunction–Associated Steatohepatitis (MASH)
  • Primary Biliary Cholangitis Knowledge Hub
  • C. difficile & Microbiome Therapeutics Knowledge Hub
  • Highlights from DDW 2026
  • Gastrointestinal Resource Center
  • Inflammatory Bowel Disease
  • NASH Resource Center
  • Highlights from DDW 2025
  • Highlights from ACG 2025 - Focus on Ulcerative Colitis
  • Highlights from ACG 2026 - Focus on Ulcerative Colitis
  • Highlights from ACG 2025 - Focus on Metabolic Dysfunction–Associated Steatohepatitis (MASH)
  • Highlights from ACG 2026 - Focus on Metabolic Dysfunction–Associated Steatohepatitis (MASH)
  • Primary Biliary Cholangitis Knowledge Hub
  • C. difficile & Microbiome Therapeutics Knowledge Hub
  • Highlights from DDW 2026

Advanced Search

Advanced Search

  • Featured:
  • Highlights from ACG 2026 - Focus on Ulcerative Colitis
  • Highlights from ACG 2026 - Focus on Metabolic Dysfunction–Associated Steatohepatitis (MASH)

Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT)

October 2019

Share:
Back to C. difficile & Microbiome Therapeutics Knowledge Hub Peer-reviewed articles

Read Full Article

Abstract

Background: Fecal microbiota transplantation (FMT) is a promising therapy for recurrent Clostridioides difficile infection (CDI).Many patients report altered bowel habits including constipation, bloating, gas and loose stool post-FMT despite resolution of CDI, and the etiology remains unclear.

Methods: This was a prospective cohort study of adult patients with recurrent CDI who underwent FMT (1) via colonoscopy with patientselected donor stool, (2) via colonoscopy from a universal stool bankdonor, or (3) via capsules from a universal stool bank. Reassessment occurred 8 weeks post-FMT. Those cured were assessed for gastrointestinal symptoms (bloating, loose stools, constipation). Multivariatelogistic regression was performed to assess predictors of post-FMT gastrointestinal symptoms.

Results: A total of 150 subjects underwent FMT for recurrent CDI, of which 68.7% (103) were female, mean age was 61.5 years±18.1 and 31 patients (20.7%) had preexisting irritable bowel syndrome. Thirty-six had FMT via colonoscopy with a patient-selected donor, 67 via colonoscopy with stool bank donors, and 47 via FMT capsules from stoolbank donors. Among those cured, 41 (31.2%) had gastrointestinal symptoms post-FMT. The factors associated with symptoms included younger age (57.2 vs. 64.1 y, P=0.03), a baseline history of irritable bowel syndrome (36.6% vs. 13.3%, P=0.002) and preexisting inflammatory bowel disease (31.7% vs. 10%, P=0.002). Small bowel exposureto donor stool was not related to symptoms (63.4% vs. 62.2%, P=0.89).

Conclusions: Altered bowel habits are a consequence of CDI and are common after FMT. This study suggests that donor type and FMT delivery modality are not related to the presence of irregular gastrointestinal symptoms after FMT.

Share

Modal body text goes here.

FocusOn logo
  • Articles
  • Multimedia
  • Blog
  • Resources
  • About FocusOn
  • Privacy Policy
  • Terms of Use

© 2026 Wolters Kluwer. All right reserved.